Moderna-Merck mRNA Melanoma Vaccine Gives Field a Boost — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna and Merck reported clinical success with a personalized mRNA vaccine for melanoma, giving the mRNA field a boost after a rough stretch of political whiplash.
- Ryan Sullivan, a Mass General Brigham melanoma physician and immunologist who has worked with Moderna, said cancer vaccines might "thaw some of the stigma around vaccines" by making mRNA "not a four-letter word."
- mRNA technology works by instructing cells to construct proteins by rewriting the mRNA's genetic code — the flexibility that enabled Covid-19 vaccines in under a year and now powers cancer vaccines.
- Operation Warp Speed helped fund and accelerate Covid vaccine development, with President Trump still calling it a "monumental national achievement" of his first term.
- Moderna and BioNTech built their Covid-19 vaccines on the same mRNA platform now being repurposed for oncology applications.
Why it matters: For melanoma patients, personalized mRNA vaccines represent a tangible new treatment pathway emerging from clinical data. For the broader mRNA field, Sullivan's framing matters: a successful cancer application could soften public suspicion that has dogged the technology since the Covid era, potentially unlocking political space for further development.
Ask SkimNews
